1. Бокерия Л.А., Покровский А.В., Сокуренко Г.Ю. с соавт. Национальные рекомендации по ведению пациентов с заболеваниями брахиоцефальных артерий // Российский согласительный документ. 2013. 2. Conte M.S. et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication // Journal of Vascular Surgery. 2015. Vol. 61, № 3. P. 2–41. 3. Gerhard-Herman M.D. et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines // Circulation. Ovid Technologies (Wolters Kluwer Health), 2016. Vol. 135, № 12. P. 686–725. 4. Aboyans V. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal // Eur. HeartJ. England, 2018. Vol. 39, № 9. P. 763–816. 5. Покровский А.В. с соавт. Отдаленные результаты аорто-бедренных реконструкций у больных сахарным диабетом 2 типа // Ангиология и сосудистая хирургия. 2010. Том 16, № 1. С. 48–53. 6. Norgren L. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) // J. Vasc. Surg. Elsevier BV, 2007. Vol. 45, № 1. P. 5–67. 7. Hirsch A.T. et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) // Circulation. 2006. Vol. 113, № 11. P. 463–465. 8. Савельев В.С., Кошкин В.М. Критическая ишемия нижних конечностей. М.: Медицина. 1997; 160. 9. Berridge D.C., Kessel D.O., Robertson I. Surgery versus thrombolysis for initial management of acute limb ischaemia // Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2002. 10. Ультразвуковая диагностика, практическое решение клинических проблем. Том 5, Э.И. Блют, К.Б. Бенсон, 2011 г. 11. Authors/Task Force Members et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboratio // Eur. Heart J. 2013. Vol. 34, № 39. P. 3035–3087. 12. Willigendael E.M. et al. Influence of smoking on incidence and prevalence of peripheral arterial disease // J. Vasc. Surg. 2004. Vol. 40, № 6. P. 1158–1165. 13. Duval S. et al. The Contribution of Tobacco Use to High Health Care Utilization and Medical Costs in Peripheral Artery Disease // J. Am. Coll. Cardiol. Elsevier BV, 2015. Vol. 66, № 14. P. 1566–1574. 14. Armstrong E.J. et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease // J. Vasc. Surg. Elsevier BV, 2014. Vol. 60, № 6. P. 1565–1571. 15. Pujades-Rodriguez M. et al. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937360 people in England: lifetime risks and implications for risk prediction // Int. J. Epidemiol. Oxford University Press (OUP), 2015. Vol. 44, № 1. P. 129–141. 16. Tolstrup J.S. et al. Smoking and Risk of Coronary Heart Disease in Younger, Middle-Aged, and Older Adults // Am. J. Public Health. American Public Health Association, 2014. Vol. 104, № 1. P. 96–102. 17. Selvarajah S. et al. Preoperative smoking is associated with early graft failure after infrainguinal bypass surgery // J. Vasc. Surg. Elsevier BV, 2014. Vol. 59, № 5. P. 1308–1314. 18. Hoel A.W. et al. Variation in smoking cessation after vascular operations // J. Vasc. Surg. Elsevier BV, 2013. Vol. 57, № 5. P. 1338–1344. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 81 19. Clair C. et al. Association of Smoking Cessation and Weight Change With Cardiovascular Disease Among Adults With and Without Diabetes // JAMA. American Medical Association (AMA), 2013. Vol. 309, № 10. P. 1014. 20. Patnode C.D. et al. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the U.S. Preventive Services Task Force // Ann. Intern. Med. American College of Physicians, 2015. Vol. 163, № 8. P. 608. 21. Stead L.F. et al. Physician advice for smoking cessation // Cochrane Database Syst. Rev. Wiley-Blackwell, 2013. 22. Rigotti N.A. et al. Sustained Care Intervention and Postdischarge Smoking Cessation Among Hospitalized Adults // JAMA. American Medical Association (AMA), 2014. Vol. 312, № 7. P. 719. 23. Hennrikus D. et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial // J. Am. Coll. Cardiol. Elsevier BV, 2010. Vol. 56, № 25. P. 2105–2112. 24. Rigotti N.A. et al. Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial // Circulation. Ovid Technologies (Wolters Kluwer Health), 2010. Vol. 121, № 2. P. 221–229. 25. Tonstad S. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study // Eur. Heart J. Oxford University Press (OUP), 2003. Vol. 24, № 10. P. 946–955. 26. Mills E.J. et al. Cardiovascular Events Associated With Smoking Cessation PharmacotherapiesClinical Perspective // Circulation. Ovid Technologies (Wolters Kluwer Health), 2013. Vol. 129, № 1. P. 28–41. 27. Prochaska J.J. et al. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis // BMJ. 2012. Vol. 344. P. 2856–2856. 28. Lu L. et al. Association between level of exposure to secondhand smoke and peripheral arterial disease: Cross-sectional study of 5686 never smokers // Atherosclerosis. Elsevier BV, 2013. Vol. 229, № 2. P. 273– 276. 29. Aung P.P. et al. Lipid-lowering for peripheral arterial disease of the lower limb. // Cochrane database Syst. Rev. Wiley-Blackwell, 2007. № 4. P. 123. 30. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions // J. Vasc. Surg. Elsevier BV, 2007. Vol. 45, № 4. P. 645–654; discussion 653-4. 31. Antoniou G.A. et al. Statin therapy in lower limb peripheral arterial disease: Systematic review and metaanalysis // Vascul. Pharmacol. Elsevier BV, 2014. Vol. 63, № 2. P. 79–87. 32. Kumbhani D.J. et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry // Eur. Heart J. Oxford University Press (OUP), 2014. Vol. 35, № 41. P. 2864–2872. 33. Vogel T.R. et al. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population // Circ. Cardiovasc. Interv. Elsevier BV, 2013. Vol. 6, № 6. P. 694–700. 34. Mohler E.R. Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease // Circulation. Ovid Technologies (Wolters Kluwer Health), 2003. Vol. 108, № 12. P. 1481– 1486. 35. Piepoli M.F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice // Rev. Española Cardiol. (English Ed. Elsevier BV, 2016. Vol. 69, № 10. P. 939. 36. Murphy S.A. et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial // J. Am. Coll. Cardiol. Elsevier BV, 2016. Vol. 67, № 4. P. 353–361. 37. Meade T. et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial // BMJ, 2002. Vol. 325, № 7373. P. 1139. 38. Sabatine M.S. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2017. Vol. 376, № 18. P. 1713–1722. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 82 39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. 2002. Vol. 288, № 23. P. 2981–2997. 40. Adler A.I. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // BMJ, 2000. Vol. 321, № 7258. P. 412–419. 41. Singer D.R.J., Kite A. Management of Hypertension in Peripheral Arterial Disease: Does the Choice of Drugs Matter? // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2008. Vol. 35, № 6. P. 701–708. 42. Mancia G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Eur. Heart J. 2013. Vol. 34, № 28. P. 2159–2219. 43. Диагностика и лечение артериальной гипертонии: клинические рекомендации. Кардиологическийвестник. 2015; Том X, № 1. С. 3–30. 44. Diehm C. et al. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication // J. Hypertens. Ovid Technologies (Wolters Kluwer Health), 2011. Vol. 29, № 7. P. 1448–1456. 45. Paravastu S.C.V., Mendonca D.A., Da Silva A. Beta blockers for peripheral arterial disease // Cochrane Database Syst. Rev. Wiley-Blackwell, 2013. 46. Espinola-Klein C. et al. Beta-Blockers in Patients With Intermittent Claudication and Arterial Hypertension: Results From the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial // Hypertension. Ovid Technologies (Wolters Kluwer Health), 2011. Vol. 58, № 2. P. 148–154. 47. Bavry A.A. et al. Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease: Findings From the INternational VErapamil-SR/Trandolapril STudy // Hypertension. Ovid Technologies (Wolters Kluwer Health), 2009. Vol. 55, № 1. P. 48–53. 48. De Buyzere M.L. et al. Management of Hypertension in Peripheral Arterial Disease // Prog. Cardiovasc. Dis. Elsevier BV, 2008. Vol. 50, № 4. P. 238–263. 49. SPRINT Research Group et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2015. Vol. 373, № 22. P. 2103–2116. 50. Yusuf S. et al. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators // N. Engl. J. Med, 2000. Vol. 342, № 3. P. 145–153. 51. Ostergren J. et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease // Eur. Heart J. Oxford University Press (OUP), 2004. Vol. 25, № 1. P. 17–24. 52. Yusuf S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. 2008. Vol. 358, № 15. P. 1547–1559. 53. Zanchetti A. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial // Circulation. Ovid Technologies (Wolters Kluwer Health), 2002. Vol. 106, № 19. P. 2422–2427. 54. Zanchetti A. et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS--A Randomized Double-Blind Trial // Stroke. Ovid Technologies (Wolters Kluwer Health), 2004. Vol. 35, № 12. P. 2807–2812. 55. Paravastu S.C.V. et al. Beta Blockers for Peripheral Arterial Disease // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2009. Vol. 38, № 1. P. 66–70. 56. Radack K. ß-Adrenergic Blocker Therapy Does Not Worsen Intermittent Claudication in Subjects With Peripheral Arterial Disease // Arch. Intern. Med. American Medical Association (AMA), 1991. Vol. 151, № 9. P. 1769. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 83 57. Schmit K. et al. Comparative Effectiveness Review of Antiplatelet Agents in Peripheral Artery Disease // J. Am. Heart Assoc. Ovid Technologies (Wolters Kluwer Health), 2014. Vol. 3, № 6. P. 1330–1330. 58. Belch J. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease // BMJ, 2008. Vol. 337. P. 1840–1840. 59. Fowkes F.G.R. Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial // JAMA. American Medical Association (AMA), 2010. Vol. 303, № 9. P. 841. 60. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ, 2002. Vol. 324, № 7329. P. 71–86. 61. Berger J.S. et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials // JAMA. American Medical Association (AMA), 2009. Vol. 301, № 18. P. 1909–1919. 62. Hiatt W.R. et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2017. Vol. 376, № 1. P. 32–40. 63. Pickett C.A. et al. Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis // Lancet. Elsevier BV, 2008. Vol. 371, № 9624. P. 1587–1594. 64. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. Elsevier BV, 1996. Vol. 348, № 9038. P. 1329–1339. 65. Cacoub P.P. et al. Patients with peripheral arterial disease in the CHARISMA trial // Eur. Heart J. Oxford University Press (OUP), 2008. Vol. 30, № 2. P. 192–201. 66. Bhatt D.L. et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events // N. Engl. J. Med. 2006. Vol. 354, Р. 1706–1717. 67. Anand S.S. et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial // J. Am. Coll. Cardiol. 2018. Vol. 71, № 20, Р. 2306-2315. 68. Anand S.S. et al. Rivaroxaban with or without aspirin in patients with stable– peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial // Lancet. 2018. Vol. 391, № 10117, Р. 219–229. 69. Bedenis R. et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery // Cochrane Database Syst. Rev. Wiley-Blackwell, 2015. 70. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial // Lancet (London, England). Elsevier BV, 2000. Vol. 355, № 9201. P. 346–351. 71. Johnson W.C. et al. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: A prospective randomized study // J. Vasc. Surg. Elsevier BV, 2002. Vol. 35, № 3. P. 413–421. 72. Monaco M. et al. Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients // J. Vasc. Surg. Elsevier BV, 2012. Vol. 56, № 1. P. 96–105. 73. Belch J.J.F., Dormandy J. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial // J. Vasc. Surg. Elsevier BV, 2010. Vol. 52, № 4. P. 825–833. 74. Dake M.D. et al. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery CLINICAL PERSPECTIVE // Circulation. Ovid Technologies (Wolters Kluwer Health), 2016. Vol. 133, № 15. P. 1472–1483. 75. Laird J.R. et al. Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions // J. Am. Coll. Cardiol. Elsevier BV, 2015. Vol. 66, № 21. P. 2329–2338. 76. Dagher N.N. et al. Pharmacotherapy Before and After Revascularization: Anticoagulation, Antiplatelet Agents, and Statins // Semin. Vasc. Surg. Elsevier BV, 2007. Vol. 20, № 1. P. 10–14. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 84 77. Franzone A. et al. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease // JAMA Cardiol. American Medical Association (AMA), 2016. Vol. 1, № 7. P. 795. 78. Bonaca M.P. et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2015. Vol. 372, № 19. P. 1791–1800. 79. Bonaca M.P. et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease // J. Am. Coll. Cardiol. Elsevier BV, 2016. Vol. 67, № 23. P. 2719–2728. 80. Kirchhof P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // Eur. Heart J. Oxford University Press (OUP), 2016. Vol. 37, № 38. P. 2893–2962. 81. Winkel T.A. et al. Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease: Data from the REduction of Atherothrombosis for Continued Health (REACH) Registry // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2010. Vol. 40, № 1. P. 9–16. 82. Resnick H.E. et al. Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality: The Strong Heart Study // Circulation. Ovid Technologies (Wolters Kluwer Health), 2004. Vol. 109, № 6. P. 733–739. 83. Jude E.B. et al. Peripheral Arterial Disease in Diabetic and Nondiabetic Patients: A comparison of severity and outcome // Diabetes Care. American Diabetes Association, 2001. Vol. 24, № 8. P. 1433–1437. 84. Smith S.C. et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update // J. Am. Coll. Cardiol. Elsevier BV, 2011. Vol. 58, № 23. P. 2432–2446. 85. Peripheral Arterial Disease in People With Diabetes // Diabetes Care. American Diabetes Association, 2003. Vol. 26, № 12. P. 3333–3341. 86. Singh S. et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty // Vasc. Med. SAGE Publications, 2014. Vol. 19, № 4. P. 307–314. 87. Takahara M. et al. The Influence of Glycemic Control on the Prognosis of Japanese Patients Undergoing Percutaneous Transluminal Angioplasty for Critical Limb Ischemia // Diabetes Care. American Diabetes Association, 2010. Vol. 33, № 12. P. 2538–2542. 88. Dorresteijn J.A.N. et al. Patient education for preventing diabetic foot ulceration // Cochrane Database Syst. Rev. Wiley-Blackwell, 2014. 89. Miller J.D. et al. How to do a 3-minute diabetic foot exam // J. Fam. Pract. 2014. Vol. 63, № 11. P. 646–656. 90. Prompers L. et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study // Diabetologia. Springer Nature, 2008. Vol. 51, № 5. P. 747–755. 91. Pickwell K. et al. Predictors of Lower-Extremity Amputation in Patients With an Infected Diabetic Foot Ulcer // Diabetes Care. American Diabetes Association, 2015. Vol. 38, № 5. P. 852–857. 92. Lavery L.A. et al. Reevaluating the Way We Classify the Diabetic Foot: Restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot // Diabetes Care. American Diabetes Association, 2007. Vol. 31, № 1. P. 154–156. 93. Juergens J.L., Barker N.W., Hines E.A. Arteriosclerosis Obliterans: Review of 520 Cases with Special Reference to Pathogenic and Prognostic Factors // Circulation. Ovid Technologies (Wolters Kluwer Health), 1960. Vol. 21, № 2. P. 188–195. 94. Piepoli M.F. et al. Guidelines: Editor’s choice: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice // Eur. Heart J. Oxford University Press, 2016. Vol. 37, № 29. P. 2315. 95. Westin G.G. et al. Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb Ischemia // J. Am. Coll. Cardiol. Elsevier BV, 2014. Vol. 63, № 7. P. 682–690. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 85 96. Momsen A.H. et al. Drug Therapy for Improving Walking Distance in Intermittent Claudication: A Systematic Review and Meta-analysis of Robust Randomised Controlled Studies // European Journal of Vascular and Endovascular Surgery. 2009. Vol. 38, № 4. P. 463–474. 97. Shahin Y. et al. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication // Atherosclerosis. Elsevier BV, 2013. Vol. 231, № 2. P. 283–290. 98. Bagger J.P. et al. Effect of Verapamil in Intermittent Claudication: A Randomized, Double-Blind, PlaceboControlled, Cross-over Study After Individual Dose-Response Assessment // Circulation. Ovid Technologies (Wolters Kluwer Health), 1997. Vol. 95, № 2. P. 411–414. 99. Soga Y. et al. Beta-blocker Treatment Does Not Worsen Critical Limb Ischemia in Patients Receiving Endovascular Therapy // J. Atheroscler. Thromb. Japan Atherosclerosis Society, 2015. Vol. 22, № 5. P. 481– 489. 100. Mirault T. et al. Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease // Medicine (Baltimore). Ovid Technologies (Wolters Kluwer Health), 2017. Vol. 96, № 5. P. 5916. 101. Gardner A.W., Poehlman E.T. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis // JAMA. 1995; Vol. 274, № 12. Р. 975–80. 102. Lane R. et al. Exercise for intermittent claudication // Cochrane Database Syst. Rev. Wiley-Blackwell, 2014. 103. Hiatt W.R. et al. Benefit of exercise conditioning for patients with peripheral arterial disease // Circulation. Ovid Technologies (Wolters Kluwer Health), 1990. Vol. 81, № 2. P. 602–609. 104. Parmenter B.J., Dieberg G., Smart N.A. Exercise Training for Management of Peripheral Arterial Disease: A Systematic Review and Meta-Analysis // Sport. Med. Springer Nature, 2014. Vol. 45, № 2. P. 231–244. 105. Pilz M. et al. Evaluation of 6- and 12-month supervised exercise training on strength and endurance parameters in patients with peripheral arterial disease // Wien. Klin. Wochenschr. Springer Nature, 2014. Vol. 126, № 11–12. P. 383–389. 106. Regensteiner J.G., Steiner J.F., Hiatt W.R. Exercise training improves functional status in patients with peripheral arterial disease // J. Vasc. Surg. Elsevier BV, 1996. Vol. 23, № 1. P. 104–115. 107. Regensteiner J.G. Exercise in the Treatment of Claudication: Assessment and Treatment of Functional Impairment // Vasc. Med. SAGE Publications, 1997. Vol. 2, № 3. P. 238–242. 108. Stewart K.J. et al. Exercise Training for Claudication // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2002. Vol. 347, № 24. P. 1941–1951. 109. Brenner I., Parry M., Brown C.A. Exercise Interventions for Patients with Peripheral Arterial Disease: A Review of the Literature // Phys. Sportsmed. Informa UK Limited, 2012. Vol. 40, № 2. P. 41–55. 110. Corra U. et al. Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: Key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitat // Eur. Heart J. Oxford University Press (OUP), 2010. Vol. 31, № 16. P. 1967–1974. 111. Fokkenrood H.J.P. et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. // Cochrane database Syst. Rev. 2013. № 8. P. 5263. 112. Murphy T.P., Cutlip D.E., Regensteiner J.G. Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Study // J. Vasc. Surg. Elsevier BV, 2012. Vol. 55, № 3. P. 886–887. 113. Murphy T.P. et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: The CLEVER study // J. Am. Coll. Cardiol. 2015. Vol. 65, № 10. P. 999–1009. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 86 114. Guidon M., McGee H. One-year effect of a supervised exercise programme on functional capacity and quality of life in peripheral arterial disease // Disabil. Rehabil. 2013. Vol. 35, № 5. P. 397–404. 115. Gommans L.N.M. et al. Safety of supervised exercise therapy in patients with intermittent claudication // J. Vasc. Surg. Elsevier BV, 2015. Vol. 61, № 2. P. 512–518. 116. Fakhry F. et al. Long-term clinical effectiveness of supervised exercise therapyversusendovascular revascularization for intermittent claudication from a randomized clinical trial // Br. J. Surg. Wiley-Blackwell, 2013. Vol. 100, № 9. P. 1164–1171. 117. Mazari F.A.K. et al. Early Outcomes From a Randomized, Controlled Trial of Supervised Exercise, Angioplasty, and Combined Therapy in Intermittent Claudication // Ann. Vasc. Surg. Elsevier BV, 2010. Vol. 24, № 1. P. 69–79. 118. Fakhry F. et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication // JAMA. American Medical Association (AMA), 2015. Vol. 314, № 18. P. 1936. 119. Mays R.J. et al. Community walking programs for treatment of peripheral artery disease // J. Vasc. Surg. Elsevier BV, 2013. Vol. 58, № 6. P. 1678–1687. 120. Al-Jundi W. et al. Systematic Review of Home-based Exercise Programmes for Individuals with Intermittent Claudication // J. Vasc. Surg. Elsevier BV, 2013. Vol. 58, № 6. P. 1722–1723. 121. Bäck M. et al. Home-based supervised exercise versus hospital-based supervised exercise or unsupervised walk advice as treatment for intermittent claudication: A systematic review // J. Rehabil. Med. Acta Dermato-Venereologica, 2015. Vol. 47, № 9. P. 801–808. 122. McDermott M.M. et al. Home-Based Walking Exercise in Peripheral Artery Disease: 12-Month Follow-up of the Goals Randomized Trial // J. Am. Heart Assoc. Ovid Technologies (Wolters Kluwer Health), 2014. Vol. 3, № 3. P. 711. 123. Lauret G.-J. et al. Modes of exercise training for intermittent claudication // Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012. 124. McDermott M.M. Statin Use and Leg Functioning in Patients With and Without Lower-Extremity Peripheral Arterial Disease // Circulation. Ovid Technologies (Wolters Kluwer Health), 2003. Vol. 107, № 5. P. 757–761. 125. Gargiulo G. et al. Use of statins in lower extremity artery disease: a review // BMC Surg. Springer Nature, 2012. Vol. 12, Suppl 1. P. 15. 126. Robertson L., Andras A. Prostanoids for intermittent claudication // Cochrane Database Syst. Rev. Wiley-Blackwell, 2013. 127. Stevens J.W. et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication // Br. J. Surg. Wiley-Blackwell, 2012. Vol. 99, № 12. P. 1630–1638. 128. Bedenis R. et al. Cilostazol for intermittent claudication // Cochrane Database Syst. Rev. WileyBlackwell, 2014. 129. Hood S.C. et al. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. // CMAJ. 1996. Vol. 155, № 8. P. 1053–1059. 130. Winblad B. et al. Therapeutic Use of Nicergoline // Clin. Drug Investig. 2008. Vol. 28, № 9. P. 533– 552. 131. Schönenberger F. Clinical study on nicergoline in peripheral arteriopathies. // Farmaco. Prat. 1976. Vol. 31, № 11. P. 561–567. 132. Pasotti C. et al. Therapeutic action of nicergoline in the treatment of cerebrovascular and peripheral disorders // Farmaco. Prat. 1974. Vol. 29, № 9. P. 508–519. 133. Cascone A. et al. Controlled study with nicergoline and placebo in cerebral and peripheral vascular insufficiency in the aged // Minerva Cardioangiol. 1975. Vol. 26, № 1–2. P. 95–100. 134. Coscia M. Effects of nicergoline in peripheral arteriopathies of the lower limbs. Double-blind study. // Minerva Cardioangiol. 1972. Vol. 20, № 9. P. 497–504. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 87 135. Meilhac B. et al. Double-blind randomized comparative study of nicergoline naftidrofuryl on the quality of life in chronic obliterative arteriopathy of lower limbs with intermittent claudication // Therapie. 1997. Vol. 52, № 3. P. 179–186. 136. Di Perri T. et al. Effects of a Single I.V. Dose of Nicergoline on Haemorrheological and Haemodynamic Parameters in Peripheral Vascular Disease. A Double-Blind, Cross-over Study // Proof of Therapeutical Effectiveness of Nootropic and Vasoactive Drugs. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. P. 159–168. 137. Khandanpour N. et al. Homocysteine and Peripheral Arterial Disease: Systematic Review and Metaanalysis // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2009. Vol. 38, № 3. P. 316–322. 138. Lonn E. Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial // Can. J. Cardiol. 2006. Vol. 22, № 1. P. 47–53. 139. Lonn E. et al. Homocysteine lowering with folic acid and B vitamins in vascular disease // N. Engl. J. Med. 2006. Vol. 354, № 15. P. 1567–1577. 140. Indes J.E. et al. Clinical Outcomes of 5358 Patients Undergoing Direct Open Bypass or Endovascular Treatment for Aortoiliac Occlusive Disease: A Systematic Review and Meta-Analysis // J. Endovasc. Ther. International Society of Endovascular Specialists, 2013. Vol. 20, № 4. P. 443–455. 141. Grimme F.A.B. et al. Editor’s Choice – First Results of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique for Aortoiliac Occlusive Disease // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2015. Vol. 50, № 5. P. 638–647. 142. Anderson J.L. et al. Clinical Practice Guidelines on Perioperative Cardiovascular Evaluation: Collaborative Efforts Among the ACC, AHA, and ESC // Circulation. Ovid Technologies (Wolters Kluwer Health), 2014. Vol. 130, № 24. P. 2213–2214. 143. Klinkert P. et al. Saphenous Vein Versus PTFE for Above-Knee Femoropopliteal Bypass. A Review of the Literature // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2004. Vol. 27, № 4. P. 357–362. 144. Malgor R.D. et al. A systematic review of treatment of intermittent claudication in the lower extremities // J. Vasc. Surg. Elsevier BV, 2015. Vol. 61, № 3. P. 54–73. 145. Brass E.P. et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia // J. Vasc. Surg. Elsevier BV, 2006. Vol. 43, № 4. P. 752–759. 146. Mills J.L. et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: Risk stratification based on Wound, Ischemia, and foot Infection (WIfI) // J. Vasc. Surg. Elsevier BV, 2014. Vol. 59, № 1. P. 220–234. 147. Dominguez A. et al. Endovascular therapy for critical limb ischemia // Expert Rev. Cardiovasc. Ther. Informa UK Limited, 2015. Vol. 13, № 4. P. 429–444. 148. Lumsden A.B. et al. Medical and Endovascular Management of Critical Limb Ischemia // J. Endovasc. Ther. International Society of Endovascular Specialists, 2009. Vol. 16, № SupplementII. P. II31-II62. 149. Adam D.J. et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial // Lancet (London, England). 2005. Vol. 366, № 9501. P. 1925–1934. 150. Bradbury A.W. et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making // J. Vasc. Surg. Elsevier BV, 2010. Vol. 51, № 5. P. 52–68. 151. Zeller T. et al. Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia // J. Am. Coll. Cardiol. Elsevier BV, 2014. Vol. 64, № 15. P. 1568–1576. 152. Menard M.T. et al. The BEST-CLI trial: a multidisciplinary effort to assess whether surgical or endovascular therapy is better for patients with critical limb ischemia // Semin. Vasc. Surg. Elsevier BV, 2014. Vol. 27, № 1. P. 82–84. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 88 153. Popplewell M.A. et al. Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial // Trials. Springer Nature, 2016. Vol. 17, № 1. 154. Teraa M. et al. Critical Limb Ischemia: Current Trends and Future Directions // J. Am. Heart Assoc. Ovid Technologies (Wolters Kluwer Health), 2016. Vol. 5, № 2. P. 2938. 155. Rutherford R.B. et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version // J. Vasc. Surg. Elsevier BV, 1997. Vol. 26, № 3. P. 517–538. 156. Savji N. et al. Association Between Advanced Age and Vascular Disease in Different Arterial Territories // J. Am. Coll. Cardiol. Elsevier BV, 2013. Vol. 61, № 16. P. 1736–1743. 157. Collet J.-P. et al. Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study // Int. J. Cardiol. Elsevier BV, 2018. Vol. 254. P. 36–42. 158. Naylor A.R. et al. Carotid Artery Disease and Stroke During Coronary Artery Bypass:a Critical Review of the Literature // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2002. Vol. 23, № 4. P. 283–294. 159. Lin J.C. et al. Clinical utility of carotid duplex ultrasound prior to cardiac surgery // J. Vasc. Surg. Elsevier BV, 2016. Vol. 63, № 3. P. 710–714. 160. Aboyans V. et al. Renal Artery Stenosis in Patients with Peripheral Artery Disease: Prevalence, Risk Factors and Long-term Prognosis // Eur. J. Vasc. Endovasc. Surg. Elsevier BV, 2017. Vol. 53, № 3. P. 380– 385. 161. Aboyans V. Polyvascular Disease: Definition, Epidemiology, Relevance // PanVascular Medicine. Springer Berlin Heidelberg, 2015. P. 4779–4810. 162. Ahmed B. et al. Prevalence of Significant Asymptomatic Carotid Artery Disease in Patients with Peripheral Vascular Disease: A Meta-Analysis // J. Vasc. Surg. Elsevier BV, 2009. Vol. 49, № 3. P. 814. 163. Durand D.J. et al. Mandatory versus selective preoperative carotid screening: a retrospective analysis // Ann. Thorac. Surg. Elsevier BV, 2004. Vol. 78, № 1. P. 159–166. 164. Fowkes F.G.R. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study // Eur. Heart J. Oxford University Press (OUP), 2006. Vol. 27, № 15. P. 1861–1867. 165. Mukherjee D. et al. Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events) // Am. J. Cardiol. Elsevier BV, 2007. Vol. 100, № 1. P. 1–6. 166. Subherwal S. et al. Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-ST-Segment-Elevation Myocardial Infarction // Circ. Cardiovasc. Qual. Outcomes. Ovid Technologies (Wolters Kluwer Health), 2012. Vol. 5, № 4. P. 541–549. 167. Gallino A. et al. Non-coronary atherosclerosis // Eur. Heart J. Oxford University Press (OUP), 2014. Vol. 35, № 17. P. 1112–1119. 168. Cho I. et al. Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Nonfatal Myocardial Infarction in Subjects Without Chest Pain Syndrome From the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Mult // Circulation. Ovid Technologies (Wolters Kluwer Health), 2012. Vol. 126, № 3. P. 304–313. 169. Bhatt D.L. et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes // Eur. Heart J. Oxford University Press (OUP), 2009. Vol. 30, № 10. P. 1195–1202. 170. Montalescot G. et al. 2013 ESC guidelines on the management of stable coronary artery disease // Eur. Heart J. Oxford University Press, 2013. Vol. 34, № 38. P. 2949–3003. 171. Rauchhaus M. et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure // Circulation. Ovid Technologies (Wolters Kluwer Health), 2000. Vol. 102, № 25. P. 3060–3067. 172. Kahan T. The importance of myocardial fibrosis in hypertensive heart disease // J. Hypertens. Ovid Technologies (Wolters Kluwer Health), 2012. Vol. 30, № 4. P. 685–687. 173. O’Rourke M.F. et al. The Cardiovascular Continuum extended: Aging effects on the aorta and microvasculature // Vasc. Med. SAGE Publications, 2010. Vol. 15, № 6. P. 461–468. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей 89 174. Duscha B.D. et al. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure // J. Am. Coll. Cardiol. Elsevier BV, 2002. Vol. 39, № 7. P. 1170–1174. 175. Mancini D.M. et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure // Circulation. Ovid Technologies (Wolters Kluwer Health), 1992. Vol. 85, № 4. P. 1364–1373. 176. Hedberg P. et al. Left ventricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular disease: prevalence and association with location of arterial disease // Eur. J. Heart Fail. WileyBlackwell, 2014. Vol. 16, № 6. P. 625–632. 177. Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J. Oxford University Press (OUP), 2016. Vol. 37, № 27. P. 2129–2200. 178. Yamasaki S. et al. Presence of Diastolic Dysfunction in Patients With Peripheral Artery Disease // Angiology. SAGE Publications, 2013. Vol. 64, № 7. P. 540–543. 179. Meltzer A.J. et al. Heart failure is associated with reduced patency after endovascular intervention for symptomatic peripheral arterial disease // J. Vasc. Surg. Elsevier BV, 2012. Vol. 55, № 2. P. 353–362. 180. Inglis S.C. et al. Peripheral arterial disease and chronic heart failure: a dangerous mix // Heart Fail. Rev. Springer Nature, 2012. Vol. 18, № 4. P. 457–464. 181. Jones W.S. et al. Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION) // Am. J. Cardiol. 2011. Vol. 108, № 3. P. 380–384. 182. Inglis S.C. et al. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA) // Eur. J. Heart Fail. Wiley-Blackwell, 2010. Vol. 12, № 7. P. 698–705. 183. Ahmed M.I. et al. Effects of Peripheral Arterial Disease on Outcomes in Advanced Chronic Systolic Heart Failure: A Propensity-Matched Study // Circ. Hear. Fail. Ovid Technologies (Wolters Kluwer Health), 2009. Vol. 3, № 1. P. 118–124. 184. Adams D.H. et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis // N. Engl. J. Med. 2014. Vol. 370, № 19. P. 1790–1798. 185. Smith C.R. et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2011. Vol. 364, № 23. P. 2187–2198. 186. Sinning J.-M. et al. The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation // Am. Heart J. Elsevier BV, 2012. Vol. 164, № 1. P. 102–110. 187. Erdogan H.B. et al. In Which Patients Should Sheathless IABP be Used? An Analysis of Vascular Complications in 1211 Cases // J. Card. Surg. Wiley-Blackwell, 2006. Vol. 21, № 4. P. 342–346. 188. Ohman J.W. et al. The effect of extremity vascular complications on the outcomes of cardiac support device recipients // J. Vasc. Surg. Elsevier BV, 2014. Vol. 59, № 6. P. 1622–1627.